FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
about
Fibroblast growth factor 23The use of fibroblast growth factor 23 testing in patients with kidney disease.Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline.Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients.Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure.Low serum calcium is associated with poor renal outcomes in chronic kidney disease stages 3-4 patients.Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion.Proteinuria Increases Plasma Phosphate by Altering Its Tubular HandlingFGF-23/Vitamin D Axis in Type 1 Diabetes: The Potential Role of Mineral Metabolism in Arterial Stiffness.Elevated Fibroblast Growth Factor 23 Concentration: Prediction of Mortality among Chronic Kidney Disease Patients.Update on immunoglobulin a nephropathy. Part II: Clinical, diagnostic and therapeutical aspects.Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology.What's new in FGF23 research?Association of a reduction in central obesity and phosphorus intake with changes in urinary albumin excretion: the PREMIER studyDisordered FGF23 and mineral metabolism in children with CKDFibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study.Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative reviewTreatment of IgA nephropathy and Henoch-Schönlein nephritis.Biomarkers in IgA nephropathy: relationship to pathogenetic hits.Proteomic biomarkers in kidney disease: issues in development and implementation.Phosphate and FGF-23 homeostasis after kidney transplantation.Dietary Phosphorus Intake and the Kidney.IgA nephropathy: association of C4d with clinical and histopathological findings and possible role of IgM.Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only.Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.
P2860
Q26829294-CC074576-AF0C-47BB-83B0-2963D4CA5C17Q33835743-70734805-B411-41B1-BE40-D91B81B0AE66Q33873450-E75E684D-E4E7-4E33-AF9D-25BDB62E00BBQ34204949-ED037416-E0FE-437C-8482-9E2D5083F0D9Q34255342-B437DA82-0472-4A88-852D-46C71E4782BEQ34629938-6E8F8842-8B61-4079-B5EE-46D7B5739B08Q35069203-490D1043-C7A8-4D7E-B20E-5100D4AC4DA9Q35790525-F7356CE0-FCA7-4CCF-8B04-8AC0B69D1869Q35804988-5F6D5D9F-6F8F-4D0F-B6BF-D766BEE7E387Q36423189-2B133A1B-4989-42C1-9DA6-F37E3279D534Q36447934-749FEDDA-5586-4EF5-9888-900FC2F8EB50Q36810501-64E095A7-3631-45F7-B4EA-2F2D5B8F962EQ37056389-AC56DF01-1996-4500-8F6B-663B74FC91C7Q37258125-CFA4891E-EF3C-4700-BEAD-9E3BD70E173AQ37553097-20E3BE43-71BA-48F0-B2C1-73D312E2D19FQ37589683-6A4645CE-0C0D-4E58-99D0-2A3D9A2103D2Q37695914-8D3056D0-3437-4822-91F6-713C89B40621Q38094888-4F4CB646-3941-4BF1-8ACF-3A1CCDFC278CQ38157013-08A35B95-BF87-484C-9972-844352404BC7Q38341211-922D953E-EA4E-4968-ACCA-0151084049A7Q38594874-C6E4D0D3-3527-4C14-BBEE-BEA3C03F7A68Q38725971-CF7D2DE3-9E81-40C6-845E-BB3BC680910BQ40576443-3381AA77-B58D-43CE-A6FD-E281CB09F283Q46004871-8D29AE51-FD33-4C03-823F-2219BCF19E97Q48200863-96DE372A-D57C-4F3F-A2FB-5D31639107DEQ53605401-AC985E86-9EB5-442A-B5C7-7228490E1387
P2860
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@ast
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@en
type
label
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@ast
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@en
prefLabel
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@ast
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@en
P2093
P2860
P356
P1476
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
@en
P2093
Iva Gunnarsson
Sara Olivecrona
Stefan H Jacobson
Tobias E Larsson
P2860
P304
P356
10.2215/CJN.10331011
P577
2012-03-01T00:00:00Z